Bladder Cancer - Pipeline Review, H1 2018

  • ID: 4564092
  • Drug Pipelines
  • 999 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bavarian Nordic A/S
  • Cytori Therapeutics Inc
  • Horizon Pharma Plc
  • MELEMA Pharma GmbH
  • Philogen SpA
  • MORE
Bladder Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2018, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

This latest pipeline guide Bladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 52, 55, 1, 67, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 3, 1, 12 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bavarian Nordic A/S
  • Cytori Therapeutics Inc
  • Horizon Pharma Plc
  • MELEMA Pharma GmbH
  • Philogen SpA
  • MORE
Introduction

Bladder Cancer - Overview

Bladder Cancer - Therapeutics Development

Bladder Cancer - Therapeutics Assessment

Bladder Cancer - Companies Involved in Therapeutics Development

Bladder Cancer - Drug Profiles

Bladder Cancer - Dormant Projects

Bladder Cancer - Discontinued Products

Bladder Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Bladder Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bladder Cancer - Pipeline by 4SC AG, H1 2018

Bladder Cancer - Pipeline by Abivax SA, H1 2018

Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Bladder Cancer - Pipeline by Alligator Bioscience AB, H1 2018

Bladder Cancer - Pipeline by Altor BioScience Corp, H1 2018

Bladder Cancer - Pipeline by Amgen Inc, H1 2018

Bladder Cancer - Pipeline by AndroScience Corp, H1 2018

Bladder Cancer - Pipeline by ANP Technologies Inc, H1 2018

Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2018

Bladder Cancer - Pipeline by Archivel Farma SL, H1 2018

Bladder Cancer - Pipeline by Array BioPharma Inc, H1 2018

Bladder Cancer - Pipeline by Asana BioSciences LLC, H1 2018

Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018

Bladder Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2018

Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2018

Bladder Cancer - Pipeline by Bayer AG, H1 2018

Bladder Cancer - Pipeline by BeiGene Ltd, H1 2018

Bladder Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Bladder Cancer - Pipeline by Biocad, H1 2018

Bladder Cancer - Pipeline by BioCancell Ltd, H1 2018

Bladder Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018

Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Bladder Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Bladder Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2018

Bladder Cancer - Pipeline by Celgene Corp, H1 2018

Bladder Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018

Bladder Cancer - Pipeline by Celprogen Inc, H1 2018

Bladder Cancer - Pipeline by Celsion Corp, H1 2018

Bladder Cancer - Pipeline by Celyad SA, H1 2018

Bladder Cancer - Pipeline by Cold Genesys Inc, H1 2018

Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Bladder Cancer - Pipeline by CytomX Therapeutics Inc, H1 2018

Bladder Cancer - Pipeline by Cytori Therapeutics Inc, H1 2018

Bladder Cancer - Pipeline by Eddingpharm Inc, H1 2018

Bladder Cancer - Pipeline by Eisai Co Ltd, H1 2018

Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2018

Bladder Cancer - Pipeline by Eli Lilly and Co, H1 2018

Bladder Cancer - Pipeline by Elsalys Biotech SAS, H1 2018

Bladder Cancer - Pipeline by EpiThany Inc, H1 2018

Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2018

Bladder Cancer - Pipeline by Exelixis Inc, H1 2018

Bladder Cancer - Pipeline by Exicure Inc, H1 2018

Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Bladder Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2018

Bladder Cancer - Pipeline by Gene Signal International SA, H1 2018

Bladder Cancer - Pipeline by Genentech Inc, H1 2018

Bladder Cancer - Pipeline by Genmab A/S, H1 2018

Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Bladder Cancer - Pipeline by H3 Biomedicine Inc, H1 2018

Bladder Cancer - Pipeline by Hamlet Pharma AB, H1 2018

Bladder Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Bladder Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H1 2018

Bladder Cancer - Pipeline by HitGen LTD, H1 2018

List of Figures

Number of Products under Development for Bladder Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • Abivax SA
  • Adaptimmune Therapeutics Plc
  • Alligator Bioscience AB
  • Altor BioScience Corp
  • Amgen Inc
  • AndroScience Corp
  • ANP Technologies Inc
  • APIM Therapeutics AS
  • Archivel Farma SL
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Asieris Pharmaceuticals Co Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • BeyondSpring Pharmaceuticals Inc
  • Biocad
  • BioCancell Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • Biomics Biotechnologies Co Ltd
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celprogen Inc
  • Celsion Corp
  • Celyad SA
  • Cold Genesys Inc
  • Corvus Pharmaceuticals Inc
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • Eddingpharm Inc
  • Eisai Co Ltd
  • Eleven Biotherapeutics Inc
  • Eli Lilly and Co
  • Elsalys Biotech SAS
  • EpiThany Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Five Prime Therapeutics Inc
  • Gene Signal International SA
  • Genentech Inc
  • Genmab A/S
  • GlaxoSmithKline Plc
  • H3 Biomedicine Inc
  • Hamlet Pharma AB
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • HitGen LTD
  • Horizon Pharma Plc
  • Immunocore Ltd
  • Immupharma Plc
  • Imugene Ltd
  • Incanthera Ltd
  • Incyte Corp
  • InteRNA Technologies BV
  • Iovance Biotherapeutics Inc
  • Johnson & Johnson
  • Kite Pharma Inc
  • Laboratoires Pierre Fabre SA
  • LipoMedix Pharmaceutical Inc
  • Loxo Oncology Inc
  • Lycera Corp
  • MacroGenics Inc
  • Marina Biotech Inc
  • MaxiVAX SA
  • MedImmune LLC
  • MELEMA Pharma GmbH
  • Merck & Co Inc
  • Merck KGaA
  • MetaMax Ltd
  • Moleculin Biotech Inc
  • MTG Biotherapeutics Inc
  • NanoCarrier Co Ltd
  • NantKwest Inc
  • Novartis AG
  • OncoTherapy Science Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Optimum Therapeutics LLC
  • Oxford BioTherapeutics Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • Pieris Pharmaceuticals Inc
  • Polaris Pharmaceuticals Inc
  • Provecs Medical GmbH
  • Provectus Biopharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • Rexahn Pharmaceuticals Inc
  • Samyang Holdings Corp
  • Sanofi
  • Seattle Genetics Inc
  • Shionogi & Co Ltd
  • Sierra Oncology Inc
  • Sillajen Biotherapeutics
  • Sitka Biopharma Inc
  • Spectrum Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Taris Biomedical LLC
  • Theralase Technologies Inc
  • Tocagen Inc
  • Tolero Pharmaceuticals Inc
  • UbiVac LLC
  • UroGen Pharmaceuticals Ltd
  • Vakzine Projekt Management GmbH
  • Vault Pharma Inc
  • Vaxeal Holding SA
  • Vaxiion Therapeutics Inc
  • Viralytics Ltd
  • Vyriad Inc
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll